Digital Evolution of Mental Healthcare & Stakeholder Adoption

Revisit our recorded webinar to hear why promoting the long-term benefits of your products to the overall healthcare system will result in therapeutic success.

The author(s)

  • Will Knopp Account Manager, Health CS&F
Get in touch

The pandemic has irrevocably upended the state of patient care in the U.S., with many of these changes likely to persist indefinitely. Already a growing sector of the healthcare industry, digital therapeutics and remote-care technology quickly became buzz words within the industry as millions of practices, physicians, and patients engaged with the technology. Broader familiarity with and support for telehealth and digital healthcare tools among physicians and patients has been a boon for digital therapeutic manufacturers eager to extoll the virtue and value of these technologies.

However, in addition to providing opportunities for innovation, the pandemic has exposed vulnerabilities and bare spots within our healthcare system. Mental health professionals, while already understaffed to treat the current patient population, are expected to see a massive rise in number of patients and services requested in the wake of COVID-19. Digital therapeutics show promise in addressing these demands, but the extent of their effectiveness will depend entirely on their adoption and level of access provided by insurers. Payers are adamant about their internal evaluation frameworks for digital therapeutics and it is essential that all manufacturers be mindful of these throughout the commercial process in order to ensure the successful launch of their digital solution.

Revisit our recorded webinar for results from new Ipsos research with national/regional payers, to help manufacturers refine their digital health offers. During this session, expect to hear more about how promoting the long-term benefits of their products to the overall healthcare system in terms of resources and expenses saved will result therapeutic success.

Listen in for these key take-aways:

  1. The widespread use of telemedicine during the COVID-19 pandemic has elevated the general public’s awareness and acceptance of digital therapeutics. This momentum is a positive development for digital therapeutic developers and awareness and willingness to adopt are highly correlated sentiments among patients. The forced utilization of digital therapies and healthcare services during the pandemic-induced lockdowns has greatly accelerated the timeline for broad adoption of digital therapeutics in the market.
  2. Economic considerations will be crucial to the success of any digital therapeutic. Favorable reimbursement and access terms is necessary for provider and patient adoption. Reimbursement of digital therapeutics generally must be formalized as a distinct medical benefit if they are ever to receive favorable coverage and comprehensive utilization. A commitment to robust clinical trials and outcomes data will aide discussions with payer organizations and secure satisfactory terms.
  3. Promotion within and collaboration with employer-sponsored health plans provide excellent avenues for rapid adoption of digital therapeutics and platforms. Therapeutic solutions that improve the management of chronic illnesses are most appealing to these stakeholders as the economic benefits are significant.

The author(s)

  • Will Knopp Account Manager, Health CS&F

Consumer & Shopper